Indication

For the treatment of adult and paediatric patients 12 years of age and older, with solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion:

  • who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
  • who have not received a prior NTRK inhibitor
  • who have no satisfactory treatment options

Medicine details

Medicine name:
entrectinib (Rozlytrek)
SMC ID:
SMC2295
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
08 March 2021
SMC meeting date:
02 February 2021
Patient group submission deadline:
05 October 2020